Talon Therapeutics, Inc.·4

Dec 23, 4:06 PM ET

DEITCHER STEVEN R 4

4 · Talon Therapeutics, Inc. · Filed Dec 23, 2010

Insider Transaction Report

Form 4
Period: 2010-12-21
DEITCHER STEVEN R
DirectorPresident & CEO
Transactions
  • Award

    Stock Option (right to buy)

    2010-12-21+1,635,0001,635,000 total
    Exercise: $0.49Exp: 2020-12-21Common Stock (1,635,000 underlying)
Holdings
  • Common Stock

    5,000
  • Stock Option (right to buy)

    Exercise: $6.96Exp: 2017-08-24Common Stock (25,000 underlying)
    25,000
  • Stock Option (right to buy)

    Exercise: $4.48Exp: 2017-12-14Common Stock (162,500 underlying)
    162,500
  • Stock Option (right to buy)

    Exercise: $0.56Exp: 2019-02-24Common Stock (75,000 underlying)
    75,000
  • Stock Option (right to buy)

    Exercise: $0.92Exp: 2020-06-07Common Stock (87,500 underlying)
    87,500
  • Stock Option (right to buy)

    Exercise: $6.60Exp: 2017-05-21Common Stock (100,000 underlying)
    100,000
  • Stock Option (right to buy)

    Exercise: $0.76Exp: 2020-02-16Common Stock (250,000 underlying)
    250,000
Footnotes (6)
  • [F1]On 9/10/10, the Company completed a one-for-four reverse stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to 9/10/10 have been adjusted to reflect the one-for-four reverse stock split.
  • [F2]100% vested
  • [F3]25,000 shares vest on each of 2/24/10, 2/24/11 and 2/24/12.
  • [F4]One-third of the shares vest on 2/16/11 and the remaining two-thirds vest in 24 equal monthly installments thereafter.
  • [F5]One-third of the shares vest on 6/7/11 and the remaining two-thirds vest in 24 equal monthly installments thereafter.
  • [F6]Shares vest in 48 equal monthly installments beginning 1/21/11.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT